Cover Image
市場調查報告書

裘馨氏肌肉萎縮症:開發平台分析

Duchenne Muscular Dystrophy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232813
出版日期 內容資訊 英文 283 Pages
訂單完成後即時交付
價格
Back to Top
裘馨氏肌肉萎縮症:開發平台分析 Duchenne Muscular Dystrophy - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 283 Pages
簡介

裘馨氏肌肉萎縮症 是引起肌肉無力,鏈接到X染色體的疾病。有這個疾病的遺傳基因在X染色體中,編碼於Dystrophin蛋白。 Dystrophin是在肌肉細胞內支撐組織結構不可或缺的物質。症狀通常在 6歲左右或比其年幼時出現,可觀察到疲勞、學習障礙、知的障礙、肌肉無力、進行性步行困難。

本報告提供裘馨氏肌肉萎縮症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等新聞和發表。

簡介

  • 調查範圍

裘馨氏肌肉萎縮症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Acceleron Pharma, Inc.
  • Anagenesis Biotechnology
  • Asklepios BioPharmaceutical, Inc.
  • Bamboo Therapeutics, Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Capricor Therapeutics, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • 第一三共
  • Debiopharm International S.A.
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • EryDel SPA
  • FibroGen, Inc.
  • Galapagos NV
  • Genethon
  • GTx, Inc.
  • Idera Pharmaceuticals, Inc.
  • Italfarmaco S.p.A.
  • La Jolla Pharmaceutical Company
  • Marathon Pharmaceuticals, LLC
  • Marina Biotech, Inc.
  • Merck KGaA
  • Milo Biotechnology LLC
  • MyoTherix Inc.
  • NicOx S.A.
  • 日本新藥
  • nLife Therapeutics, S.L.
  • Nobelpharma Co., Ltd.
  • Pfizer Inc.
  • Prothelia, Inc.
  • PTC Therapeutics, Inc.
  • RASRx, LLC
  • ReveraGen BioPharma, Inc.
  • Sanofi
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics, Inc.
  • Summit Therapeutics Plc
  • 大鵬藥品工業
  • WAVE Life Sciences Ltd.
  • Zambon Company S.p.A.

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 4-P001
  • AAV1-Foliistatin
  • ACE-083
  • alisporivir
  • 裘馨氏肌肉萎縮症用Dystrophin活性反義寡核苷酸 1
  • 裘馨氏肌肉萎縮症用Dystrophin活性反義寡核苷酸
  • 裘馨氏型/貝克氏肌肉萎縮症用肌肉生長抑制素抑制反義寡核苷酸
  • 裘馨氏肌肉萎縮症用 ACVR2B抑制反義寡核苷酸
  • 裘馨氏肌肉萎縮症用反義RNAi寡核苷酸
  • 遺傳性疾病、肌肉骨骼障礙用Calcineurin活性核酸適體
  • arbekacin
  • ARM-210
  • AT-300
  • ataluren
  • Biostrophin
  • BMBD-001
  • BMN-044
  • BMN-045
  • BMN-053
  • BMS-986089
  • CAP-1002
  • CAT-1004
  • CAT-1040
  • CAT-1041
  • DA-4210
  • deflazacort
  • dexamethasone sodium phosphate
  • domagrozumab
  • drisapersen
  • 裘馨氏肌肉萎縮症治療藥
  • DS-5141b
  • DT-200
  • enobosarm
  • eteplirsen
  • FG-3019
  • 裘馨氏肌肉萎縮症用遺傳基因療法
  • 裘馨氏型/肢帶型肌萎縮症用Dysferlin活性遺傳基因療法
  • 裘馨氏肌肉萎縮症用Dystrophin活性遺傳基因療法
  • givinostat
  • Gtx-027
  • IB-DMD
  • idebenone
  • IMO-8400
  • LJPC-30Sa
  • LJPC-30Sb
  • MG-53
  • MP-101
  • Myomir
  • naproxcinod
  • NBD Peptide
  • NS-065
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 1
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 2
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 3
  • 缺血性心臟疾病、裘馨氏肌肉萎縮症用寡核苷酸
  • OSX-200
  • poloxamer
  • PRO-052
  • PRO-055
  • PRT-01
  • 肌肉萎縮症用組換蛋白質
  • 肌肉萎縮症用Utrophin活性組換蛋白質
  • 裘馨氏肌肉萎縮症用組換蛋白質
  • rimeporide
  • RTC-13
  • 裘馨氏肌肉萎縮症用小分子
  • 裘馨氏肌肉萎縮症用Dystrophin活性小分子
  • 裘馨氏肌肉萎縮症用小分子
  • 裘馨氏肌肉萎縮症用Utrophin標靶藥物
  • SMT-022357
  • SMTC-1100
  • SRP-4008
  • SRP-4044
  • SRP-4045
  • SRP-4050
  • SRP-4052
  • SRP-4053
  • SRP-4055
  • 裘馨氏肌肉萎縮症用Dystrophin活性幹細胞療法
  • Stryka-516
  • Stryka-969
  • StrykaPro-1
  • 裘馨氏肌肉萎縮症用合成肽
  • tadalafil
  • TAS-205
  • TVN-102
  • TXA-127
  • Verolone
  • ZP-049
  • ■最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8342IDB

Summary

Global Markets Direct's, 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2016', provides an overview of the Duchenne Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy
  • The report reviews pipeline therapeutics for Duchenne Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Duchenne Muscular Dystrophy therapeutics and enlists all their major and minor projects
  • The report assesses Duchenne Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Duchenne Muscular Dystrophy Overview
  • Therapeutics Development
    • Pipeline Products for Duchenne Muscular Dystrophy - Overview
    • Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis
  • Duchenne Muscular Dystrophy - Therapeutics under Development by Companies
  • Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes
  • Duchenne Muscular Dystrophy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Duchenne Muscular Dystrophy - Products under Development by Companies
  • Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes
  • Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Anagenesis Biotechnology
    • Asklepios BioPharmaceutical, Inc.
    • BioMarin Pharmaceutical Inc.
    • Bristol-Myers Squibb Company
    • Capricor Therapeutics, Inc.
    • Catabasis Pharmaceuticals, Inc.
    • Daiichi Sankyo Company, Limited
    • Debiopharm International SA
    • Editas Medicine, Inc.
    • EryDel SPA
    • FibroGen, Inc.
    • Galapagos NV
    • Genethon
    • GTx, Inc.
    • GW Pharmaceuticals Plc
    • Idera Pharmaceuticals, Inc.
    • Italfarmaco S.p.A.
    • La Jolla Pharmaceutical Company
    • Lexicon Pharmaceuticals, Inc.
    • Marathon Pharmaceuticals, LLC
    • Marina Biotech, Inc.
    • Merck KGaA
    • Milo Biotechnology LLC
    • Mitochon Pharmaceuticals, Inc.
    • MyoTherix Inc.
    • NicOx S.A.
    • Nippon Shinyaku Co., Ltd.
    • Nobelpharma Co., Ltd.
    • Pfizer Inc.
    • Pluristem Therapeutics Inc.
    • Prothelia, Inc.
    • PTC Therapeutics, Inc.
    • RASRx, LLC
    • ReveraGen BioPharma, Inc.
    • Santhera Pharmaceuticals Holding AG
    • Sarepta Therapeutics, Inc.
    • Summit Therapeutics Plc
    • Taiho Pharmaceutical Co., Ltd.
    • WAVE Life Sciences Ltd.
    • Zambon Company S.p.A.
  • Duchenne Muscular Dystrophy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 4-P001 - Drug Profile
    • AAV1-Foliistatin - Drug Profile
    • ACE-083 - Drug Profile
    • alisporivir - Drug Profile
    • Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
    • Antisense Oligonucleotides to Inhibit ACVR2B for Duchenne Muscular Dystrophy - Drug Profile
    • Antisense RNAi Oligonucleotides for Duchenne Muscular Dystrophy - Drug Profile
    • Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
    • arbekacin - Drug Profile
    • ARM-210 - Drug Profile
    • AT-300 - Drug Profile
    • ataluren - Drug Profile
    • Biostrophin - Drug Profile
    • BMBD-001 - Drug Profile
    • BMS-986089 - Drug Profile
    • CAP-1002 - Drug Profile
    • CAP-2003 - Drug Profile
    • CAT-1004 - Drug Profile
    • DA-4210 - Drug Profile
    • deflazacort - Drug Profile
    • dexamethasone sodium phosphate - Drug Profile
    • domagrozumab - Drug Profile
    • Drug for Duchenne Muscular Dystrophy - Drug Profile
    • Drugs for Duchenne Muscular Dystrophy - Drug Profile
    • DS-5141 - Drug Profile
    • DT-200 - Drug Profile
    • enobosarm - Drug Profile
    • eteplirsen - Drug Profile
    • ezutromid - Drug Profile
    • Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile
    • Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile
    • Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Gene Therapy to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile
    • givinostat - Drug Profile
    • Gtx-027 - Drug Profile
    • IB-DMD - Drug Profile
    • idebenone - Drug Profile
    • IMO-8400 - Drug Profile
    • LJPC-30Sa - Drug Profile
    • LJPC-30Sb - Drug Profile
    • LX-2931 - Drug Profile
    • MG-53 - Drug Profile
    • MP-101 - Drug Profile
    • Myomir - Drug Profile
    • naproxcinod - Drug Profile
    • NS-065 - Drug Profile
    • Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Oligonucleotides 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Oligonucleotides 2 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Oligonucleotides 3 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • OSX-200 - Drug Profile
    • pamrevlumab - Drug Profile
    • PLX-PAD - Drug Profile
    • poloxamer - Drug Profile
    • PRO-052 - Drug Profile
    • PRO-055 - Drug Profile
    • PRT-01 - Drug Profile
    • Recombinant Protein for Muscular Dystrophy - Drug Profile
    • Recombinant Protein to Activate Utrophin for Muscular Dystrophies - Drug Profile
    • Recombinant Proteins for Duchenne Muscular Dystrophy - Drug Profile
    • rimeporide - Drug Profile
    • RTC-13 - Drug Profile
    • SB-001 - Drug Profile
    • SB-002 - Drug Profile
    • SGT-001 - Drug Profile
    • Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Small Molecules for Duchenne Muscular Dystrophy - Drug Profile
    • Small Molecules for Duchenne Muscular Dystrophy - Drug Profile
    • Small Molecules to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Small Molecules to Agonize Cannabinoid Receptor for Duchenne Muscular Dystrophy - Drug Profile
    • SMT-022357 - Drug Profile
    • SRP-4008 - Drug Profile
    • SRP-4044 - Drug Profile
    • SRP-4045 - Drug Profile
    • SRP-4050 - Drug Profile
    • SRP-4052 - Drug Profile
    • SRP-4053 - Drug Profile
    • SRP-4055 - Drug Profile
    • Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
    • Stryka-516 - Drug Profile
    • Stryka-969 - Drug Profile
    • StrykaPro-1 - Drug Profile
    • Synthetic Peptides for Duchene Muscle Dystrophy - Drug Profile
    • TAS-205 - Drug Profile
    • TVN-102 - Drug Profile
    • TXA-127 - Drug Profile
    • vamorolone - Drug Profile
    • ZP-049 - Drug Profile
  • Duchenne Muscular Dystrophy - Dormant Projects
  • Duchenne Muscular Dystrophy - Discontinued Products
  • Duchenne Muscular Dystrophy - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Duchenne Muscular Dystrophy, H2 2016
  • Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnology, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Debiopharm International SA , H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Editas Medicine, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by FibroGen, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Genethon, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by GTx, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by La Jolla Pharmaceutical Company, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Merck KGaA, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by MyoTherix Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by RASRx, LLC, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Summit Therapeutics Plc, H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd., H2 2016
  • Duchenne Muscular Dystrophy - Pipeline by Zambon Company S.p.A., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Duchenne Muscular Dystrophy - Dormant Projects, H2 2016
  • Duchenne Muscular Dystrophy - Dormant Projects (Contd..1), H2 2016
  • Duchenne Muscular Dystrophy - Dormant Projects (Contd..2), H2 2016
  • Duchenne Muscular Dystrophy - Dormant Projects (Contd..3), H2 2016
  • Duchenne Muscular Dystrophy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Duchenne Muscular Dystrophy, H2 2016
  • Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top